As we previously wrote, ASCO’s focus this year was on driving the benefits of precision medicine approaches in oncology to more patients. This was reflected in several ways in the news coming out of the conference, including: Progress Against Important, Difficult-to-Target Biomarkers The ASCO news was particularly good this year for patients with...
We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma, colon cancer and breast cancer, including triple-negative breast cancer. Here, we cover other targeted therapies....